← Back to Search

Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer (eVOLVE-01 Trial)

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2.4 years
Awards & highlights

Summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2.4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2.4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Objective Response rate (ORR)
Secondary study objectives
Area Under the Curve (AUC)
Disease Control Rate (DCR)
Duration of Response (DOR)
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and PemetrexedExperimental Treatment3 Interventions
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.
Group II: Arm 1 B Volrustomig dose regimen 2 + Carboplatin and PemetrexedExperimental Treatment3 Interventions
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6120
Pemetrexed
2014
Completed Phase 3
~5550

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,352 Previous Clinical Trials
288,646,689 Total Patients Enrolled
~80 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top